June Hwu

Array ( [id] => 15866333 [patent_doc_number] => 20200140570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders [patent_app_type] => utility [patent_app_number] => 16/447085 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16447085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258857 [patent_doc_number] => 20210371842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => ANTIDOTES TO FACTOR XA INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/254146 [patent_app_country] => US [patent_app_date] => 2019-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609918 [patent_doc_number] => 20220152197 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-05-19 [patent_title] => COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/251695 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609918 [patent_doc_number] => 20220152197 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-05-19 [patent_title] => COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/251695 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711251 [patent_doc_number] => 20200102391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/438639 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408045 [patent_doc_number] => 20200024344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA [patent_app_type] => utility [patent_app_number] => 16/435166 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19745 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147895 [patent_doc_number] => 20190352425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => ASSAY TO DETECT HUMAN DPP-4 [patent_app_type] => utility [patent_app_number] => 16/433174 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15326857 [patent_doc_number] => 20200003758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY [patent_app_type] => utility [patent_app_number] => 16/429673 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16429673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589725 [patent_doc_number] => 20200071397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/428624 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16428624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962926 [patent_doc_number] => 20210214425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTS [patent_app_type] => utility [patent_app_number] => 17/057867 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178231 [patent_doc_number] => 20190359707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => Anti-Sirpa Antibodies and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 16/421692 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496321 [patent_doc_number] => 20200048349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => ANTI-CD3 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/418082 [patent_app_country] => US [patent_app_date] => 2019-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16418082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646679 [patent_doc_number] => 20200085869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES [patent_app_type] => utility [patent_app_number] => 16/413158 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 109990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102454 [patent_doc_number] => 11542329 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Antibodies targeting Glycoprotein VI [patent_app_type] => utility [patent_app_number] => 17/055528 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 41400 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 219 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117257 [patent_doc_number] => 20190345261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => ASPARTATE BETA-HYDROXYLASE CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/409250 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16991882 [patent_doc_number] => 20210230302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => ANTI-CHI3L1 ANTIBODIES FOR THE DETECTION AND/OR TREATMENT OF NONALCOHOLIC FATTLY LIVER DISEASE/ NONALCOHOLIC STEATONHEPATITIS AND SUBSEQUENT COMPLICATIONS [patent_app_type] => utility [patent_app_number] => 17/053634 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19338574 [patent_doc_number] => 12048745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Methods for detecting and reversing immune therapy resistance [patent_app_type] => utility [patent_app_number] => 16/400595 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 92 [patent_no_of_words] => 27775 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16400595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990322 [patent_doc_number] => 20210228742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => IN VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCT [patent_app_type] => utility [patent_app_number] => 17/051137 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035433 [patent_doc_number] => 20190328721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => METHOD OF ACTIVATING DENDRITIC CELLS [patent_app_type] => utility [patent_app_number] => 16/394223 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16394223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778078 [patent_doc_number] => 20210115156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/046838 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046838 [rel_patent_id] =>[rel_patent_doc_number] =>)